JUN 30, 2016 07:30 AM PDT

Proteome centric precision medicine: embracing pathological diversity

Speakers
  • Director, Advanced Clinical Biosystems Research Institute and Director of the Basic Science Research of the Barbra Streisand Woman's Heart Center
    Biography

      Dr. Van Eyk, Ph.D., is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. The institute mandate is to facilitate application of proteomics throughout medicine and enhance translation of new therapies and biomarkers to clinical use through the application of innovative technologies. Her research laboratory studies the underlying molecular mechanism of heart and vascular disease using a large number of proteomic methodologies focusing on the site-specific identification and quantification of disease induced post-translational modifications. The underlying concept of competitive post-translational modifications that act as molecular switches that sense and respond to dynamic changes within the cell.


      Widely regarded as an international leader in the field of proteomics, Van Eyk is best known for developing a number of lab tests to determine the presence of certain proteins or amino acids in patients' blood, which could indicate whether they have experienced a heart attack or have heart disease. She earned her Bachelor of Science degree in biology and chemistry at the University of Waterloo, Canada and her doctorate in biochemistry at the University of Alberta, Edmonton. During her directorship of the Johns Hopkins National Heart, Lung, and Blood Institute Proteomics Center, a National Heart, Lung, and Blood Institute Proteomics Center located at the Johns Hopkins University School of Medicine, Van Eyk also served as director of the Bayview Proteomics Group and as professor of medicine in the Division of Cardiology in Biological Chemistry and Biomedical Engineering. She has over 210 peer reviewed manuscripts, reviews, book chapters and has co-edited two books.


    Abstract:
    Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways.  Personalized medicine requires diagnosing a specific individual’s disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. This concept has driven decision-making processes around new drug trials that take into account altered pathological proteomes.  Furthermore, this work has led us to consider the need for continuous patent-centric biomarker analysis at the population level. We will share our work on developing technical pipelines for health and pathological discovery and targeted proteomic analysis that reduces the barriers around gender, age and social economic status. We have begun down this path with production of system suitability and quality control measures, development of quantitative small and large multiplex assays and will discuss the remaining challenges involved and requirement for population-scale proteomics.

    Learning Objectives:
    • Understand the underlying premise that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease
    • See data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy

    Show Resources
    You May Also Like
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    FEB 26, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 26, 2019 09:00 AM PST
    DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    FEB 20, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 20, 2019 09:00 AM PST
    DATE:  February 20, 2019TIME:  9:00am PST  ...
    FEB 27, 2019 08:00 AM PST
    C.E. CREDITS
    FEB 27, 2019 08:00 AM PST
    DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
    Loading Comments...
    Show Resources